

2017 OPA Midyear Meeting Learning Objectives

ACPE #0129-0000-17-083-L04-P

Pharmacists' Roles in Value-Based Care Models

Cathy Kuhn, R.Ph., PharmD, FAPhA and Hosain Aghamoosa, R.Ph., PharmD

At the completion of this activity, the participant will be able to:

1. define value and its impact on the provision of health care;
2. describe the various arrangements of value-based care models; and
3. identify roles and opportunities for pharmacists within value-based care models

ACPE #0129-0000-17-084-L04-P

Opportunities for Pharmacists in Value-Based Care: Panel Discussion

Moderator: Marc A. Sweeney

At the completion of this activity, the participant will be able to:

1. discuss various roles of pharmacists in value-based care;
2. identify challenges to implementing value-based care in a traditional care setting ; and
3. describe how pharmacists can influence future value-based care models.

ACPE #0129-0000-17-085-L03-P

Pharmacy Law and Rules Update 2017

Paul Schad, R.Ph.

At the completion of this activity, the participant will be able to:

1. identify recent changes in Ohio laws and rules which impact pharmacy practice;
2. describe the proposed rules for pharmacy technician registration;
3. explain new requirements for opioid prescriptions and dispensing of multiple simultaneous refills; and
4. review commonly asked questions about new pharmacy laws and rules.

ACPE #0129-0000-17-086-L01-P

An Overview of Mental Health Disorders: The Pharmacist's Role in Optimizing Care and Reducing Stigma

Kelsey Kresser Schmuhl, R.Ph., PharmD

At the completion of this activity, the participant will be able to:

1. describe the prevalence of common mental health disorders;
2. compare risk factors, symptoms, pharmacology and common pharmacological treatment for depression, anxiety, bipolar disorder and schizophrenia;
3. discuss the pharmacist's role in the provision of long acting injectable antipsychotics; and
4. define stigma and evaluate the pharmacist's role in reducing stigma.

ACPE #0129-0000-17-087-L01-P

Parkinson's Disease in 2017 and Beyond

Charles Mosler, R.Ph., PharmD, CGP, FASCP

At the completion of this activity, the participant will be able to:

1. assess potential risks of the use of medications in a patient with Parkinson's Disease;
2. evaluate medications commonly used to treat Parkinson's Disease;

3. create a care plan for medication treatment of a patient with Parkinson's Disease; and
4. compare and contrast historical, current and future treatment of Parkinson's Disease.

ACPE #0129-0000-17-088-L01-P

Pain Management: A Primer for Pharmacists

Jessica Geiger-Hayes PharmD, BCPS, CPE

At the completion of this activity, the participant will be able to:

1. describe somatic, visceral and neuropathic pain;
2. recommend treatment options for somatic, visceral and neuropathic pain; and
3. assess opportunities to implement opioid-sparing options for pain relief.

ACPE #0129-0000-17-089-L01-P

Digging Into GOLD – Overview of GOLD 2017 Guidelines

Andrew Straw, R.Ph., PharmD, BCADM

At the completion of this activity, the participant will be able to:

1. outline the medications used for the treatment of chronic obstructive pulmonary disease (COPD);
2. recognize the changes presented in the GOLD 2017 guidelines;
3. choose appropriate COPD therapy based on a patient case; and
4. explain recent findings and events that may impact care of a COPD patient.